Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer

R. V. Iaffaioli, F. Caponigro, A. Tortoriello, G. Facchini, V. Ravo, M. Maccauro, P. Dimitri, F. Crovella, P. Muto

Research output: Contribution to journalArticle

Abstract

43 patients with stage III NSCLC (non-small cell lung cancer) entered a phase II study aimed at evaluating the toxicity and the activity of a combined modality programme including an accelerated split-course schedule (type B) of thoracic radiation therapy and a combination chemotherapy with vinorelbine and carboplatin. An objective response was achieved in 18/42 evaluable patients (5 complete and 13 partial responses), for an overall response rate of 43% (95% confidence interval, 28-58%). Four complete responses had a duration which exceeded 16 months. Treatment was well tolerated; grade III myelotoxcity occurred in only 14% of patients and treatment was delayed in only 2 cases because of grade 3 oesophagitis. Both tolerability and efficacy data suggest that this regimen holds promise for the treatment of patients with stage III NSCLC.

Original languageEnglish
Pages (from-to)1901-1904
Number of pages4
JournalEuropean Journal of Cancer
Volume32
Issue number11
DOIs
Publication statusPublished - Oct 1996

Fingerprint

Carboplatin
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Radiotherapy
Thorax
Esophagitis
Appointments and Schedules
Therapeutics
Confidence Intervals
vinorelbine

Keywords

  • Accelerated split-course radiotherapy
  • Carboplatin
  • Non-small cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer. / Iaffaioli, R. V.; Caponigro, F.; Tortoriello, A.; Facchini, G.; Ravo, V.; Maccauro, M.; Dimitri, P.; Crovella, F.; Muto, P.

In: European Journal of Cancer, Vol. 32, No. 11, 10.1996, p. 1901-1904.

Research output: Contribution to journalArticle

@article{c24244cbcb1f4c4792200c84e365468d,
title = "Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer",
abstract = "43 patients with stage III NSCLC (non-small cell lung cancer) entered a phase II study aimed at evaluating the toxicity and the activity of a combined modality programme including an accelerated split-course schedule (type B) of thoracic radiation therapy and a combination chemotherapy with vinorelbine and carboplatin. An objective response was achieved in 18/42 evaluable patients (5 complete and 13 partial responses), for an overall response rate of 43{\%} (95{\%} confidence interval, 28-58{\%}). Four complete responses had a duration which exceeded 16 months. Treatment was well tolerated; grade III myelotoxcity occurred in only 14{\%} of patients and treatment was delayed in only 2 cases because of grade 3 oesophagitis. Both tolerability and efficacy data suggest that this regimen holds promise for the treatment of patients with stage III NSCLC.",
keywords = "Accelerated split-course radiotherapy, Carboplatin, Non-small cell lung cancer, Vinorelbine",
author = "Iaffaioli, {R. V.} and F. Caponigro and A. Tortoriello and G. Facchini and V. Ravo and M. Maccauro and P. Dimitri and F. Crovella and P. Muto",
year = "1996",
month = "10",
doi = "10.1016/0959-8049(96)00203-1",
language = "English",
volume = "32",
pages = "1901--1904",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "11",

}

TY - JOUR

T1 - Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer

AU - Iaffaioli, R. V.

AU - Caponigro, F.

AU - Tortoriello, A.

AU - Facchini, G.

AU - Ravo, V.

AU - Maccauro, M.

AU - Dimitri, P.

AU - Crovella, F.

AU - Muto, P.

PY - 1996/10

Y1 - 1996/10

N2 - 43 patients with stage III NSCLC (non-small cell lung cancer) entered a phase II study aimed at evaluating the toxicity and the activity of a combined modality programme including an accelerated split-course schedule (type B) of thoracic radiation therapy and a combination chemotherapy with vinorelbine and carboplatin. An objective response was achieved in 18/42 evaluable patients (5 complete and 13 partial responses), for an overall response rate of 43% (95% confidence interval, 28-58%). Four complete responses had a duration which exceeded 16 months. Treatment was well tolerated; grade III myelotoxcity occurred in only 14% of patients and treatment was delayed in only 2 cases because of grade 3 oesophagitis. Both tolerability and efficacy data suggest that this regimen holds promise for the treatment of patients with stage III NSCLC.

AB - 43 patients with stage III NSCLC (non-small cell lung cancer) entered a phase II study aimed at evaluating the toxicity and the activity of a combined modality programme including an accelerated split-course schedule (type B) of thoracic radiation therapy and a combination chemotherapy with vinorelbine and carboplatin. An objective response was achieved in 18/42 evaluable patients (5 complete and 13 partial responses), for an overall response rate of 43% (95% confidence interval, 28-58%). Four complete responses had a duration which exceeded 16 months. Treatment was well tolerated; grade III myelotoxcity occurred in only 14% of patients and treatment was delayed in only 2 cases because of grade 3 oesophagitis. Both tolerability and efficacy data suggest that this regimen holds promise for the treatment of patients with stage III NSCLC.

KW - Accelerated split-course radiotherapy

KW - Carboplatin

KW - Non-small cell lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0030272386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030272386&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(96)00203-1

DO - 10.1016/0959-8049(96)00203-1

M3 - Article

C2 - 8943672

AN - SCOPUS:0030272386

VL - 32

SP - 1901

EP - 1904

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -